Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Interleukin-9 (IL-9) is a pleiotropic cytokine belonging to the common gamma-chain (γc) family, primarily produced by Th9 cells, but also by Th2, Th17, and regulatory T cells. Traditionally, IL-9 signaling was understood to occur through a heterodimeric receptor complex consisting of the IL-9 receptor alpha (IL-9Rα) and the common gamma chain (γc), primarily in hematopoietic cells. However, recent research has identified a novel "type II" IL-9 receptor complex in airway epithelial cells, composed of IL-9Rα and the IL-13 receptor alpha 1 (IL-13Rα1) subunit. This signaling pathway activates STAT3 and induces the expression of chemokines such as CXCL3, which promotes the recruitment of CXCR2+ immune cells and contributes to airway inflammation and asthma pathogenesis. While IL-9 is a target for antagonistic therapies in respiratory disease, recombinant IL-9 is also investigated in preclinical oncology for its potential to stimulate mast cells and enhance anti-tumor immunity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on interleukin-9.